Tempus AI, Inc. (NASDAQ: TEM) announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This regulatory milestone enables the device to generate T1 and T2 inline maps, significantly enhancing its capabilities for cardiac MR image analysis.
Enhanced Cardiac Tissue Characterization
The updated Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. Unlike conventional MR images that show only brightness differences, T1 and T2 maps provide precise numerical values to cardiac tissue characteristics, helping clinicians detect conditions such as fibrosis, inflammation, or edema that may otherwise go undetected.
With its newly cleared functionality, Tempus Pixel can now generate T1 and T2 inline maps directly from raw MRI data, even when the scanner itself does not produce them. The platform calculates values at every pixel across the image to create detailed DICOM maps for comprehensive tissue assessment.
Clinical Impact and AI-Driven Insights
"This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful," said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus. "With inline maps generated by Tempus Pixel, cardiologists and radiologists gain a comprehensive view of heart tissue, enabling deeper insights into cardiac health and helping them deliver more precise, personalized care to their patients."
AI-enabled radiology platforms like Tempus Pixel enhance medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights. By improving accuracy and efficiency, the technology empowers clinicians to make faster, more informed decisions and deliver personalized patient care.
Strategic Expansion in Medical Imaging
Tempus has developed and deployed a suite of advanced algorithms across radiology and pathology, helping physicians deliver more precision, personalized care. The company's strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data—ranging from lung CT scans and chest X-rays to cardiac MRIs—into Tempus' platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus' efforts.
Tempus operates as a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care while facilitating discovery, development and delivery of optimal therapeutics.
